OTOF mutations revealed by genetic analysis of hearing loss families including a potential temperature sensitive auditory neuropathy allele

Autor: Varga, R, Avenarius, MR, Kelley, PM, Keats, BJ, Berlin, CI, Hood, LJ, Morlet, TG, Brashears, SM, Starr, A, Cohn, ES, Smith, RJH, Kimberling, WJ

Publikováno v: Varga, R; Avenarius, MR; Kelley, PM; Keats, BJ; Berlin, CI; Hood, LJ; et al.(2006). OTOF mutations revealed by genetic analysis of hearing loss families including a potential temperature sensitive auditory neuropathy allele. Journal of Medical Genetics, 43(7), 576-581. doi: 10.1136/jmg.2005.038612. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/4m09d687

Introduction: The majority of hearing loss in children can be accounted for by genetic causes. Non-syndromic hearing loss accounts for 80% of genetic hearing loss in children, with mutations in DFNB1/GJB2 being by far the most common cause. Among the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::6087e5bee4224547e358f32758219e73
http://www.escholarship.org/uc/item/4m09d687

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.

Autor: Stein L; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA., Murugesan K; Foundation Medicine Inc, Cambridge, MA, USA., Reeser JW; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Risch Z; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Wing MR; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Paruchuri A; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Samorodnitsky E; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Hoskins EL; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, USA., Dao T; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Smith A; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Le D; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Babcook MA; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Chang YS; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA., Avenarius MR; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Department of Pathology, The Ohio State University, Columbus, OH, USA., Imam M; Florida Cancer Specialists, Orlando, FL, USA., Freud AG; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA.; Department of Pathology, The Ohio State University, Columbus, OH, USA., Roychowdhury S; Comprehensive Cancer Center and James Cancer Hospital, The Ohio State University, Columbus, OH, USA. Sameek.Roychowdhury@osumc.edu.; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA. Sameek.Roychowdhury@osumc.edu.

Publikováno v: NPJ precision oncology [NPJ Precis Oncol] 2024 Sep 17; Vol. 8 (1), pp. 207. Date of Electronic Publication: 2024 Sep 17.

Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization.

Autor: Teierle SM; Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH., Huang Y; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Kittai AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Bhat SA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Grever M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Rogers KA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Zhao W; Department of Pathology, The Ohio State University, Columbus, OH., Jones D; Department of Pathology, The Ohio State University, Columbus, OH., Byrd JC; Department of Internal Medicine, The University of Cincinnati, Cincinnati, OH., Avenarius MR; Department of Pathology, The Ohio State University, Columbus, OH., Heerema NA; Department of Pathology, The Ohio State University, Columbus, OH., Woyach JA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH., Miller CR; Department of Pathology, The Ohio State University, Columbus, OH.

Publikováno v: Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7239-7242.

EGFR internal tandem duplications in fusion-negative congenital and neonatal spindle cell tumors.

Autor: Koo SC; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.; Department of Pathology, The Ohio State University, Columbus, Ohio, USA., Schieffer KM; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA., Lee K; Department of Pathology, The Ohio State University, Columbus, Ohio, USA.; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA., Gupta A; Department of Hematology, Oncology, and BMT, Nationwide Children's Hospital, Columbus, Ohio, USA., Pfau RB; Department of Pathology, The Ohio State University, Columbus, Ohio, USA.; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA., Avenarius MR, Stonerock E; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA., LaHaye S; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA., Fitch J; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA., Setty BA; Department of Hematology, Oncology, and BMT, Nationwide Children's Hospital, Columbus, Ohio, USA., Roberts R; Department of Hematology, Oncology, and BMT, Nationwide Children's Hospital, Columbus, Ohio, USA., Ranalli M; Department of Hematology, Oncology, and BMT, Nationwide Children's Hospital, Columbus, Ohio, USA., Conces MR; Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.; Department of Pathology, The Ohio State University, Columbus, Ohio, USA., Bu F; Department of Pathology, The Ohio State University, Columbus, Ohio, USA.; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA., Mardis ER; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA., Cottrell CE; Department of Pathology, The Ohio State University, Columbus, Ohio, USA.; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.; Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.

Publikováno v: Genes, chromosomes & cancer [Genes Chromosomes Cancer] 2023 Jan; Vol. 62 (1), pp. 17-26. Date of Electronic Publication: 2022 Jul 25.